It is predicted that the market size of 'gene therapy', a medical technique that modifies an individual's genes to treat ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract ...

Experts say it’s no surprise that UnitedHealthcare often ends up in the crosshairs of public and political scrutiny, as it’s ...

Rznomics Inc., a South Korean RNA therapeutics developer, has signed an agreement worth more than $1.3 billion with US pharmaceutical giant Eli Lilly & Co. to license out its novel RNA-editing ...

Report Ocean has published a new report on the Immunotherapy Drugs Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. T ...

Eli Lilly and Company announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), an injection for intravenous infusion ...

American Eli Lilly has signed technology transfer contracts for RNA therapeutics ... This shift may present opportunities for Asian, particularly South Korean, bio corporations. It suggests that if ...